Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors
The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
1. A method of reducing the risk of hospitalization for heart failure in an adult with type 2 diabetes mellitus and established cardiovascular disease comprising administering to the adult of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, wherein the ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof administered is in a pharmaceutical composition comprising 0.5-15% by weight of ertugliflozin, 10-50% by weight of microcrystalline cellulose, 10-50% by weight of dibasic calcium phosphate anhydrous, 0.5-5% croscamellose sodium, 0.5-5% by weight sodium stearyl fumarate, 0.5-2% by weight magnesium stearate, 1-6% by weight Opadry 20A, and 0.001-0.005% by weight carnuba wax.
2. The method of reducing the risk of hospitalization for heart failure in an adult with type 2 diabetes mellitus and established cardiovascular disease of claim 1 , wherein, the pharmaceutical composition comprises 5 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.
3. The method of reducing the risk of hospitalization for heart failure in an adult with type 2 diabetes mellitus and established cardiovascular disease of claim 1 , wherein, the pharmaceutical composition comprises 15 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.
4. The method of reducing the risk of hospitalization for heart failure in an adult with type 2 diabetes mellitus and established cardiovascular disease of claim 1 , wherein, the pharmaceutical composition is administered once daily.